Phase 1b/2a trial designed to evaluate the safety and feasibility of IFx-Hu2.0 in combination with Keytruda ® when administered via Interventional Radiology (IR) in patients with deep- seated tumors ...
Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as first-line treatment for advanced and metastatic Merkel cell ...
TAMPA, Fla., June 24, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to ...
This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and the first study in earlier-stage ...
Keytruda, known scientifically as pembrolizumab, is an immunotherapy drug that has transformed cancer treatment for many patients worldwide. Traditional chemotherapy works by directly attacking the ...
IFx-Hu2.0 is designed to overcome primary resistance to checkpoint inhibitors (CPIs) like Keytruda ® and has demonstrated systemic anti-tumor specific immune responses (abscopal effect) when injected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results